Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. scores highest on Torque (59) and lowest on Earnings (3). Its PosiPenta is 36.06 out of 100, weaker than most similar companies.
On the Penta Grid this week, Apimeds Pharmaceuticals US, Inc. is Grid #645 of 837 in the Healthcare sector in United States, and Grid #3,217 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. | 36.06 | 50 | 3 | 18 | 59 | 51 |
| Azitra, Inc. | 31.86 | 44 | 38 | 15 | 35 | 27 |
| Vivos Therapeutics, Inc. | 26.30 | 0 | 47 | 5 | 50 | 30 |
| Dermata Therapeutics, Inc. | 38.00 | 37 | 23 | 25 | 52 | 53 |
| Xenetic Biosciences, Inc. | 44.91 | 42 | 49 | 32 | 69 | 33 |
| Scienture Holdings, Inc. | 35.47 | 50 | 41 | 7 | 46 | 34 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.11 |
| P/B ratio | 0.06 |
EEarnings
| Trailing EPS | ₹-3412.58 |
| Forward EPS | — |
NNitro
| Price | 382.65 |
| 52-week high | 5654.48 |
| 52-week low | 143.02 |
| Fall from 52-week high | 93.2% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | 0.05 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹57 Cr |
| Insider holding | 58.70% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Apimeds Pharmaceuticals US, Inc.'s PosiPenta score?
Apimeds Pharmaceuticals US, Inc.'s PosiPenta is 36.06 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Apimeds Pharmaceuticals US, Inc. stand on the Penta Grid?
On the Penta Grid this week, Apimeds Pharmaceuticals US, Inc. is Grid #645 of 837 in the Healthcare sector in United States, and Grid #3,217 of 4,000 in United States.
Which PosiPenta pillar is strongest for Apimeds Pharmaceuticals US, Inc.?
Torque (durability), with a score of 59 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Apimeds Pharmaceuticals US, Inc.?
Earnings (growth), with a score of 3 out of 100: much weaker than most similar companies.
Has Apimeds Pharmaceuticals US, Inc.'s PosiPenta changed since last week?
No, it is unchanged at 36.06.
PositoAI is for research and education only and is not investment advice.